194 related articles for article (PubMed ID: 9408695)
41. Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients.
Fishman JA; Doran MT; Volpicelli SA; Cosimi AB; Flood JG; Rubin RH
Transplantation; 2000 Feb; 69(3):389-94. PubMed ID: 10706048
[TBL] [Abstract][Full Text] [Related]
42. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients.
Wiltshire H; Paya CV; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Zuideveld KP;
Transplantation; 2005 Jun; 79(11):1477-83. PubMed ID: 15940035
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers.
Brown F; Banken L; Saywell K; Arum I
Clin Pharmacokinet; 1999 Aug; 37(2):167-76. PubMed ID: 10496303
[TBL] [Abstract][Full Text] [Related]
44. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].
Gane E; Saliba F; Valdecasas GJ; O'Grady J; Pescovitz MD; Lyman S; Robinson CA
Lancet; 1997 Dec; 350(9093):1729-33. PubMed ID: 9413463
[TBL] [Abstract][Full Text] [Related]
45. Randomized trial of ganciclovir followed by high-dose oral acyclovir vs ganciclovir alone in the prevention of cytomegalovirus disease in pediatric liver transplant recipients: preliminary analysis.
Green M; Reyes J; Nour B; Beatty D; Kaufman M; Wilson J; Todo S; Tzakis A
Transplant Proc; 1994 Feb; 26(1):173-4. PubMed ID: 8108926
[No Abstract] [Full Text] [Related]
46. Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days.
Welker H; Farhan M; Humar A; Washington C
Transplantation; 2010 Dec; 90(12):1414-9. PubMed ID: 21076372
[TBL] [Abstract][Full Text] [Related]
47. Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study.
Sagedal S; Nordal KP; Hartmann A; Midtvedt K; Foss A; Asberg A; Degré M; Fauchald P; Rollag H
Nephrol Dial Transplant; 2003 Sep; 18(9):1899-908. PubMed ID: 12937241
[TBL] [Abstract][Full Text] [Related]
48. Comparative study of prophylactic oral ganciclovir and valacyclovir in high-risk kidney transplant recipients.
Yango A; Morrissey P; Zanabli A; Beaulieu J; Shemin D; Dworkin L; Monaco A; Gohh R
Nephrol Dial Transplant; 2003 Apr; 18(4):809-13. PubMed ID: 12637653
[TBL] [Abstract][Full Text] [Related]
49. New prophylactic treatment strategy for cytomegalovirus disease.
Lake KD
Am J Health Syst Pharm; 2003 Dec; 60(23 Suppl 8):S13-6. PubMed ID: 14686230
[TBL] [Abstract][Full Text] [Related]
50. Oral valgancyclovir versus intravenous gancyclovir for cytomegalovirus prophylaxis in kidney transplant recipients.
Said T; Nampoory MR; Pacsa AS; Essa S; Madi N; Fahim N; Abraham M; Nair P; Al-Otaibi T; Halim MA; Johny KV; Al-Mousawi M
Transplant Proc; 2007 May; 39(4):997-9. PubMed ID: 17524873
[TBL] [Abstract][Full Text] [Related]
51. Costs and consequences of cytomegalovirus disease.
Schnitzler MA
Am J Health Syst Pharm; 2003 Dec; 60(23 Suppl 8):S5-8. PubMed ID: 14686228
[TBL] [Abstract][Full Text] [Related]
52. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.
McGavin JK; Goa KL
Drugs; 2001; 61(8):1153-83. PubMed ID: 11465876
[TBL] [Abstract][Full Text] [Related]
53. Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection.
Tornatore KM; Garey KW; Saigal N; Reed K; Murray B; Ingalls E; DiFrancesco R; Forrest A; Morse G; Venuto R
Clin Transplant; 2001 Oct; 15(5):297-308. PubMed ID: 11678955
[TBL] [Abstract][Full Text] [Related]
54. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts.
Erice A; Jordan MC; Chace BA; Fletcher C; Chinnock BJ; Balfour HH
JAMA; 1987 Jun; 257(22):3082-7. PubMed ID: 3035246
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics of oral ganciclovir capsules in HIV-infected persons.
Griffy KG
AIDS; 1996 Dec; 10 Suppl 4():S3-6. PubMed ID: 9110063
[TBL] [Abstract][Full Text] [Related]
56. Prophylaxis against herpes infections in kidney transplant patients with special emphasis on CMV.
Birkeland SA; Andersen HK; Gahrn-Hansen B
Scand J Infect Dis; 1998; 30(3):221-6. PubMed ID: 9790127
[TBL] [Abstract][Full Text] [Related]
57. Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection.
Stockmann C; Roberts JK; Knackstedt ED; Spigarelli MG; Sherwin CM
Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):205-19. PubMed ID: 25428442
[TBL] [Abstract][Full Text] [Related]
58. Preemptive treatment with oral ganciclovir for pediatric renal transplantation.
Melgosa Hijosa M; García Meseguer C; Peña Garcia P; Alonso Melgar A; Espinosa Román L; Peña Carrión A; Navarro Torres M
Clin Nephrol; 2004 Apr; 61(4):246-52. PubMed ID: 15125030
[TBL] [Abstract][Full Text] [Related]
59. Cytomegalovirus transmission in pediatric renal transplant recipients during the window period.
Gangopadhyay S; Rampersaud H; Pelletier JP; Herman L; Goldstein S; Upadhyay K
Pediatr Transplant; 2016 Feb; 20(1):172-7. PubMed ID: 26691349
[TBL] [Abstract][Full Text] [Related]
60. Ganciclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients.
Anderson RD; Griffy KG; Jung D; Dorr A; Hulse JD; Smith RB
Clin Ther; 1995; 17(3):425-32. PubMed ID: 7585846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
